Analysts Anticipate Dynavax Technologies Co. (DVAX) Will Post Quarterly Sales of $1.66 Million

Equities research analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce $1.66 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Dynavax Technologies’ earnings. The lowest sales estimate is $1.00 million and the highest is $2.31 million. Dynavax Technologies posted sales of $110,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 1,409.1%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, August 1st.

On average, analysts expect that Dynavax Technologies will report full year sales of $13.28 million for the current fiscal year, with estimates ranging from $7.87 million to $18.68 million. For the next financial year, analysts forecast that the business will post sales of $101.86 million per share, with estimates ranging from $88.31 million to $115.41 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.82 million. Dynavax Technologies had a negative net margin of 31,635.17% and a negative return on equity of 60.61%. The company’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.60) EPS.

DVAX has been the topic of several recent analyst reports. Royal Bank of Canada reiterated a “buy” rating and set a $25.00 price objective on shares of Dynavax Technologies in a research report on Friday, March 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price objective on shares of Dynavax Technologies in a research report on Tuesday, May 8th. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, March 27th. BidaskClub upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, April 16th. Finally, Cowen reiterated a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $24.67.

Shares of Dynavax Technologies traded up $0.25, hitting $16.15, on Monday, MarketBeat Ratings reports. 2,807,076 shares of the company traded hands, compared to its average volume of 1,386,591. The stock has a market cap of $990.16 million, a P/E ratio of -9.34 and a beta of 0.81. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.85 and a quick ratio of 10.83. Dynavax Technologies has a 52 week low of $7.55 and a 52 week high of $24.45.

In related news, insider Michael S. Ostrach sold 4,000 shares of the business’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $15.53, for a total value of $62,120.00. Following the sale, the insider now owns 80,554 shares in the company, valued at $1,251,003.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.47% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new stake in Dynavax Technologies in the first quarter worth $199,000. Xact Kapitalforvaltning AB purchased a new position in Dynavax Technologies during the first quarter worth $200,000. Commonwealth Equity Services LLC purchased a new position in Dynavax Technologies during the first quarter worth $212,000. LPL Financial LLC purchased a new position in Dynavax Technologies during the first quarter worth $283,000. Finally, Paloma Partners Management Co purchased a new position in Dynavax Technologies during the fourth quarter worth $331,000. Institutional investors own 77.60% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply